NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered BPC-157 from Lumira? Mail in a sample (US only) and let us test it for free.

Test my supply
+16 more ↓
41%
Finnrick rating
#140 of 149 BPC-157 vendors
2 of 8 classifiable tests passed
natural 25% · customers 4.4★ (12)
methodology · Purity focus
Finnrick analysis · BPC-157

Lumira's purity-focus record is broad and recent, with GHK-Cu consistently strong and Retatrutide and Tirzepatide generally improving after earlier identity or purity misses. The catalog is dispersed: NAD+, Wolverine, BPC-157, and Tesamorelin carry repeated failures or volatility, and batch documentation gaps add uncertainty.

methodology →
vendor intelligence report
Vendor Intelligence Report: Lumira

Domain and contact records tie Lumira to the Welon/Peptidecube stack while US-shipping language points another way. The report maps privacy-protected domains, referral-code promotion, and payment/refund friction.

23 pages6 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.10
93%
12
2
Retatrutide
$1.70
81%
32
3
Tirzepatide
$0.74
78%
14
4
Ipamorelin
$1.37
58%
4
5
hCG
-
51%
5
6
GLOW
$0.57
50%
3
7
Tesamorelin
$3.40
49%
8
8
HGH
-
47%
5
9
TB-500
$2.45
42%
6
10
BPC-157selected
$1.18
41%
8
11
MOTS-c
$1.22
34%
4
12
CJC-1295
$1.79
33%
1
13
Wolverine
$1.76
20%
3
14
NAD+
$0.03
18%
5
15
CJC-IPA
$1.79
-
0
16
DSIP
$0.96
-
0
17
Epithalon
$0.64
-
0
18
Glutathione
$0.01
-
0
19
KPV
$0.95
-
0
20
Melanotan II
$0.82
-
0
21
Pinealon
$0.90
-
0
22
PT-141
$1.11
-
0
23
Sermorelin
$3.88
-
0
24
SS-31
$0.30
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%6 May 2026: 46%1 Jul 2026: 45%13 Jul 2026: 42%9 Aug 2026: 45%18 Aug 2026: 42%6 Oct 2026: 40%14 Oct 2026: 43%20 Oct 2026: 41%29 Oct 2026: current 41%46%42%41%May 26Oct 26
Showing BPC-157 tests only
Lumira BPC-157 test history
COA-backed lab tests

About Lumira test results from Finnrick

Lumira is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 14 peptides and 110 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Lumira peptides in this dataset are BPC-157 (8 tests), CJC-1295 (1 test) and GHK-Cu (12 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 110 recent tests. It also includes 2 corrections related to this vendor.

Corrections
2026-08-04
Lab correction
The original Certificate of Analysis (COA 209392) incorrectly identified the sample as **Tirzepatide** instead of the correct compound, **BPC-157**. The testing laboratory subsequently reissued the Certificate of Analysis as **COA 209656**, correcting the sample identification. The updated COA has been used to replace the incorrect information.
2026-07-26
Finnrick data entry
The COA data was corrected from 56.8 to 568 following identification of a probable parsing error during data extraction. As a result of this correction, the calculated score was updated from 3.5 to 4.1.
Free peptide testing

Ordered BPC-157 from Lumira? Mail in a sample (US only) and let us test it for free.

Test my supply